OrganOx, a world leader in normothermic machine perfusion (NMP), today announced that it has partnered with Ochre Bio, a biotech company developing RNA medicines for chronic liver diseases.

Under the terms of the partnership OrganOx will provide metra devices to Ochre Bio and its partners to evaluate the efficacy of novel RNA therapeutics using discarded donor livers perfused on the metra.

Craig Marshall, OrganOx CEO, commented:

“Thanks to the collaborative efforts of Ochre Bio, OrganOx, Yale University and LifeShare of Oklahoma, the unique capabilities of the OrganOx metra are enabling multi-day isolated organ perfusion research and facilitating a new and exciting approach to developing novel therapeutics for liver diseases. We look forward to seeing the results of this approach leave research and enter the clinic in the future.”

Share this page!